Ohio State Navbar

Directory

Don Benson Jr., MD, PhD


Staff photo

898 Biomedical Research Tower
460 W 12 Ave
Columbus, OH 43210

Phone: (614) 366-9131

Email: benson.236@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Advising Narrative

To date, I have mentored 5 student recipients of Pelotonia Undergraduate Fellowships. These competitive, peer-reviewed $12,000 one-year awards fund the students' research experience under my mentorship. These students have published first-author, peer-reviewed research manuscripts and presented first-author, peer-reviewed abstracts at international scientific meetings.

Four of these undergraduates have matriculated to medical school since completing their experiences with me. One is now poised to enter residency training with a long-term career aspiration of becoming a pediatric oncologist. The 5th student chose to eschew opportunities to attend medical school and is entering business school to obtain a Masters of Business Administration degree aspiring to a career in cancer research administration.

Postdoctoral / Researcher Advising

Since my promotion to Associate Professor, I have taken on my first post-doctoral trainee in my laboratory. She has received funding from both the National Cancer Institute (T32) and a prestigious, competitive Pelotonia Post-Doctoral Researcher Award. She has elucidated the role of the aryl hydrocarbon receptor (AHR) in myeloma biology and characterized this transcription factor as a novel target for anti-myeloma therapy. She is leading an active translational effort to develop this approach as a novel therapy for the disease. Her most recent work has been to characterize AHR as a target for therapy due to its apparent overexpression in a minute but critical subset of myeloma stem cells.

Master/Graduate Advising

Since my promotion to Associate Professor, I have become increasingly involved in graduate student advising and mentorship. My first graduate student from my laboratory, David Ciarlariello, recently successfully defended his dissertation (April, 2016) and is being actively recruited now in numerous positions in cancer immunotherapy research.

I have also served on candidacy and dissertation committees for several students and co-mentored and advised numerous trainees from multi-disciplinary backgrounds (MD, PhD, PharmD). Many of these trainees have published first-author, peer reviewed research and presented first-author, peer reviewed abstracts at international scientific meetings worldwide.

Research Funding

My research has been continually funded since my fellowship and post-doctoral training period at our institution by multiple sources including the National Cancer Institute, the American Society of Clinical Oncology, the CLL Global Research Foundation, and the American Cancer Society in addition to numerous Research Contracts and collaborations with cooperative groups and business/pharmaceutical partners as well as from philanthropic sources.

I am particularly proud of the peer-reviewed, competitive research funding obtained by students under my mentorship. Collectively, my students and trainees have earned research funding from Pelotonia, Children's Hospital of Los Angeles, The Ohio State University College of Arts and Sciences, the College of Medicine, as well as the Office of Diversity and Inclusion, MMORE, and the American Society of Hematology - HONORS program. These students in total have earned a total of $389,200 in research funding from a total of 20 individual grants under my mentorship to date.

Noteworthy Graduate Narrative

My first graduate student, David Ciarlariello, defended his dissertation successfully in April, 2016. David's fundamental and ground breaking work regarding the role of tumor cell-derived extracellular vesicles mediating immune evasion in cancer has opened new avenues of discovery as well as potential for innovative approaches to clinical translation targeting this pathway with therapeutic intent in future cancer clinical trials. Papers from his work are in process for submission for publication

Partnership Narrative

In my research career, I have established partnerships and collaborations around the country and around the world with investigators at other universities and cancer centers as well as in the biotechnology and pharmaceutical industries and with cooperative research groups.

My work has included partnerships and collaboration with:

Cooperative Groups:
- Multiple Myeloma Research Consortium
- The Alliance for Clinical Trials in Oncology (formerly CALGB)
- Cancer Immunotherapy Trials Network
- Ohio Cancer Consortium
- Center for International Blood and Marrow Transplantation
- Blood and Marrow Transplant Clinical Trials Network

Universities and Cancer Centers:
The University of Texas - MD Anderson Cancer Center, Houston, TX
University of Arkansas - Myeloma Institute for Research and Therapy, Little Rock, AR
Beth Israel Deaconness Medical Center / Dana Farber Cancer Institute, Boston MA
Fox Chase Cancer Center, Philadelphia, PA

Industry:
Novo Nordisk, Copenhagen, Denmark
Innate Pharma, Marseille, France
The Binding Site, Bath, UK
Sanofi Pharmaceuticals, Paris, France
Bristol Myers Squibb, New York, NY
Calistoga Pharmaceuticals, Seattle, WA
Gilead Pharmaceuticals, Foster City, CA
Medivation, San Francisco, CA
CureTech Ltd, Tel Aviv, Israel
Facet Biotech, San Francisco, CA
Abbott Labs, Chicago IL
Abbvie, Chicago IL

Academic Advising

2010 Paul David, The Ohio State University. Graduated 0. Interferon-mediated immune evasion in multiple myeloma
2010 David Clever, The Ohio State University. Graduated 0.
2011 Paul David, The Ohio State University. Graduated 0. Interferon-gamma mediated immunoevasive strategies in multiple myeloma (* note: my faculty status in the MCDB program prevents me from serving as the formal dissertation advisor, although David trained entirely in my laboratory and under my mentorship. I am formally listed as his "co-advisor" in the MCDB program.)
2011 Christopher Walker, The Ohio State University. Graduated 0. Therapeutic potential of FTY720-derived PP2A activating drugs and selective inhibitors of Exportin 1 in hematologic malignancies including CML and Ph+ ALL
2012 Daniel Max, The Ohio State University. Graduated 0.
2012 Rohit Menon, The Ohio State University. Graduated 0.
2012 Tiffany Hughes,, The Ohio State University. Graduated 0.
2012 Shakthi Bhaskar, The Ohio State University. Graduated 0.
2013 Meredith Conkel, The Ohio State University. Graduated 0.
2013 Jennifer Cooperrider, The Ohio State University. Graduated 0.
2013 Douglas Sborov, The Ohio State University. Graduated 0.
2013 Leah Marsh, The Ohio State University. Graduated 0.
2014 Anthony Bucca, The Ohio State University. Graduated 0.
2015 David Clever, The Ohio State University. Graduated 0.
2015 Erica Kelly, The Ohio State University. Graduated 0.
2015 Wilson Lo, The Ohio State University. Graduated 0.
2016 Peter Yu, The Ohio State University. Graduated 0.
2016 Francesca Cottini, The Ohio State University. Graduated 0.
2016 Luxi Chen, The Ohio State University. Graduated 0.
2009 - 2010 Farrukh Awan, The Ohio State University. Graduated 0.
2009 - 2011 Shauna Collins, The Ohio State University. Graduated 2011.
2010 - 2011 Amber Beery, The Ohio State University. Graduated 0.
2011 Christopher Walker, The Ohio State University. Graduated 2012.
2011 Amber D'Souza, The Ohio State University. Graduated 0.
2011 Gina Swartzel, The Ohio State University. Graduated 0.
2009 - 2012 Yousef Alghothani, The Ohio State University. Graduated 2012.
2010 - 2012 David Liebner, The Ohio State University. Graduated 0.
2010 - 2012 Mehdi Hamadani, The Ohio State University. Graduated 0.
2010 - 2012 David Clever, The Ohio State University. Graduated 0.
2011 - 2012 Jarred Burkhart, The Ohio State University. Graduated 0.
2011 - 2012 James Godfrey, The Ohio State University. Graduated 0.
2012 - 2013 Caroline Berglund, The Ohio State University. Graduated 0.
2012 - 2013 Amanda Pensiero, The Ohio State University. Graduated 0.
2013 Karalyn Larkin, The Ohio State University. Graduated 0.
2012 - 2014 Shauna Collins, The Ohio State University. Graduated 0.
2013 - 2014 Benjamin Hanson, The Ohio State University. Graduated 2014.
2014 Andrew Kim, The Ohio State University. Graduated 0.
2014 James Godfrey, The Ohio State University. Graduated 0.
2014 Sarah Wall, The Ohio State University. Graduated 0.
2014 Nicole Grieselhuber, The Ohio State University. Graduated 0.
2012 - 2015 Ed Briercheck, The Ohio State University. Graduated 0.
2012 - 2015 Maria Paskell, The Ohio State University. Graduated 2015.
2013 - 2015 Nicholas Zorko, The Ohio State University. Graduated 2015.
2013 - 2015 Meixchao Long, The Ohio State University. Graduated 0.
2014 - 2015 Luxi Chen, The Ohio State University. Graduated 0.
2014 - 2015 Mary Garcia, The Ohio State University. Graduated 2015.
2015 Evan Catton, The Ohio State University. Graduated 0.
2015 Camila Masias, The Ohio State University. Graduated 0.
2015 Polina Shindiapina, The Ohio State University. Graduated 0.
2015 Jennifer Saultz, The Ohio State University. Graduated 0.
2015 Kevin Koehler, The Ohio State University. Graduated 0.
2016 Priyanka Chablani, The Ohio State University. Graduated 2016.
 

Licenses

2003 - present Ohio Medical License: State Medical Board of Ohio
2006 - present Diplomate: American Board of Internal Medicine
2001 Comprehensive Introduction to Clinical Investigation: University of Virginia
2001 - 2004 Virginia Board of Health Professions: Virginia Board of Health Professions
2002 - 2012 Diplomate: American Board of Internal Medicine
 

Chapters in Books

ALZHEIMERS-DISEASE

Korsakoff Syndrome

Natural Killer Cell Immunity

Natural killer cell immunity

Natural killer cell immunity

 

Clinical Services

12/01/2011 HNP Inpatient Service (James Cancer Hospital)
04/01/2012 Hematology I Inpatient Service (James Cancer Hospital)
06/01/2012 BMT Inpatient Service, James (James Cancer Hospital)
09/01/2012 Hematology I Inpatient Service (James Cancer Hospital)
11/01/2012 BMT Inpatient Service (James Cancer Hospital)
01/01/2013 BMT Inpatient Service (James Cancer Hospital)
03/01/2013 Hematology III Inpatient Service (James Cancer Hospital)
05/01/2013 Hematology III Inpatient Service (James Cancer Hospital)
07/01/2013 Hematology I Inpatient Service (James Cancer Hospital)
12/01/2013 BMT Inpatient Service (James Cancer Hospital)
02/01/2014 BMT Inpatient Service (James Cancer Hospital)
03/01/2014 Hematology III Inpatient Service (James Cancer Hospital)
05/01/2014 BMT Inpatient Service (James Cancer Hospital)
07/01/2014 BMT Inpatient Service (James Cancer Hospital)
11/01/2014 Hematology 4 Inpatient Service (James Cancer Hospital)
01/01/2015 BMT Inpatient Service (James Cancer Hospital)
03/01/2015 Hematology 4 Inpatient Service (James Cancer Hospital)
06/01/2015 BMT Inpatient Service (James Cancer Hospital)
08/01/2015 BMT Inpatient Service (James Cancer Hospital)
12/01/2015 Hematology 4 Inpatient Service (James Cancer Hospital)
02/01/2016 Hematology 4 Inpatient Service (James Cancer Hospital)
04/01/2016 Hematology 4 Inpatient Service (James Cancer Hospital)

Clinical Trials

A phase I trial of AVN-944 in patients with advanced hematologic malignancies

A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma

A randomized phase II trial of rituximab versus lenalidomide versus rituximab plus lenalidomide in recurrent follicular non-Hodgkin lymphoma after relapse from a rituximab-containing regimen

Leuprolide (LHRH Agonist) to enhance immune function post-autologous stem cell transplatation

Long term observational follow up study of a multicenter, randomized double blind placebo controlled comparative trial of AMD3100 plus G-CSF versus G-CSF plus placebo to mobilize and collect > 6x10(6) CD34+ cells/kg in multiple myeloma patients for autologous transplantation

Development of a geriatric asssessment measure for older patients with cancer

Phase II study of ATRA, Arsenic Trioxide and Gematuzumab Ozogamicin in pts with previously untreated high risk APL.

Randomized Trial of maintenance vs.observation for patients with previously untreated low and intermediate risk APL, Phase III

Vorinostat (SAHA) and lenalidomide after autologous transplant for patients with multiple myeloma

Phase II study of maintenance therapy with decitabine following standard induction and cytogenetic risk-adapted intensification in previously untreated patients with AML < 60 years

A phase I/II study of combination of aurora kinase inhibitor MLN8237 and bortezomib in relapsed or refractory multiple myeloma

Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia

A trial of single autologous transplant with or without consolidation therapy versus tandem autologous transplant with lenalidomide maintenance for patients with multiple myeloma

Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia

A Phase I Study of AR-42 in Adult Patients with Advanced or Recurrent Hematologic Malignancies and Solid Tumors, for Which No Standard Therapy is Available

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 (brentuximab vedotin) and Best Supportive Care (BSC) versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma (HL) Following Autologous Stem Cell Transplant (ASCT)

A Phase Ib/II study of PCI-32765, a Btk-inhibitor, and ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases

A Phase III Randomized, Multicenter Trial Testing Whether Exercise or Stress Management Improves Functional Status and Symptoms of Autologous and Allogeneic Recipients

Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL)

Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol at a Comprehensive Cancer Center

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (MBDex) for Untreated Patients with Systemic Light-Chain (AL) Amyloidois Ineligible for Autologous Stem-cell Transplantation

A Phase 1b Fixed-dosed Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia

Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML

A phase I/II trial of rituximab, bendamustine, and obatoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma

An open-label treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma

Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation as Second Transplantation for Patients with Disease Relapse or Myelodysplasia after Prior Autologous Transplantation

Phase I Study of Lenalidomide and Conventional Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Assessing quality of life and use of resources throughout the hematopoietic stem cell transplant process

A phase 1b, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients less than or equal to 65 years old with acute myeloid leukemia (AML)

An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR), through the use of TH9402 and Light Treatment in an Ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft from a Related, Haploidentical Donor

A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications

RANDOMIZED PHASE II TRIAL OF OFATUMUMAB AND BENDAMUSTINE VS. OFATUMUMAB, BORTEZOMIB (NSC #681239, IND #58443) AND BENDAMUSTINE IN PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA

CALGB 21003: Embedded Companion to CALGB-11001

A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/Refractory Multiple Myeloma

Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients with High-Risk Acute Myeloid Diseases

An Exploratory Phase 1/2 Clinical Trial Evaluating ALD518 in subjects with Glucocorticoid-Refractory Acute Graft vs. Host Disease (GVHD) after Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma

PHASE II TRIAL OF OFATUMUMAB (CALGB IND# 112390) IN PREVIOUSLY UNTREATED FOLLICULAR NON-HODGKIN¿S LYMPHOMA (NHL)

An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma

RANDOMIZED PHASE II TRIAL OF DECITABINE-BASED INDUCTION STRATEGIES FOR PATIENTS ≥ 60 YEARS OLD WITH ACUTE MYELOID LEUKEMIA (AML)

PHASE II STUDY INCORPORATING SORAFENIB (IND 69896, NSC 724772) INTO THE THERAPY OF PATIENTS ¡Ý 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Twice-weekly in Combination with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

A Phase 1/II trial of panobinostat and lenalidomide in patients with relasped or refractory Hodgkin's Lymphoma

A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Phase I Study of the Combination of Bortezomib and Sorafenib followed by Decitabine in Elderly Patients with Acute Myeloid Leukemia

Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) FOR THE COMBINATION OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

A phase 3, randomized, open label trial of lenalidomide/dexamethasone with or without elotuzumab in subjecst with previously untreated multiple myeloma

A Randomized Study to Compare the Effect of Short- and Long-Term Schedules of Cryotherapy on the Incidence and Severity of Mucositis in High-Dose Melphalan

A Long-Term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease(GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)

Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia

A Phase 1 Study of Reolysin Alone in Patients with Relapsed or Refractory Multiple Myeloma

A phase Ib study of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma

Research database for undiagnosed cytopenias.

CALGB-21101: Embedded companion to CALGB 11002

A Phase I/II Study of Gemcitabine and Bendamustine in Patients with Relapsed or Refractory Hodgkin's Lymphoma

KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor

A phase 3, randomized, controled, open-label, multicenter safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refractory systemic light chain (AL) amyloidosis

A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals

A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies

Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease

International, randomized, double-blind placebo-controlled phase III study of the efficacy and safety of KIACTA in preventing renal function decline in pateints with AA aymloidosis

Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 monoclonal antibody CT-011 in Patients with Relapsed/Refractory Multiple Myeloma

Myeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC Protocol 114 Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis

A Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Evaluating the incidence and associated factors of acute lymphoblastic leukemia in patients previously treated for multiple myeloma

Pomalidomide, dexamethasone and carfilzomib (PdC) in myeloma (MMRC 048)

NYMC 553: A multicenter pilot study of reduced intensity allogeneic stem cell transplantation followed by adoptive cellular immunotherapy with donor derived LMP specific CTLs in patients with EBV positive refractory or recurrent Hodgkin Lymphoma (IND 15104)

A phase I study of BKM120 and ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia

A phase 1 dose escalation safety and pharmacokinetic study of multiple intravenous administrations of a humanized monoclonal antibody (SAR650984) against CD38 in patients with selected CD38+ hematological malignancies

Longitudinal study of immune mediated disorders after allogeneic HCT protocol

Phase II study of subcutaneous Velcade and oral cyclophosphamide-based induction followed by sequential maitenance therapy with Velcade and Revlimid for nwely diagnosed multiple myeloma in non-transplant cadidates: An entirely non-intravenous regimen

A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease

Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-versus-Host-Disease

A phase I/II study of pomalidomide, dexamethasone and ixazomib vs. pomalidomide / dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor-based therapy

A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma

Comprehensive Frailty Assessment

Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)

A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation

A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

A phase 1b/2 multicenter, open label, dose-escalation study to determine the maximal tolerated dose, safety, and efficacy of ACY-1215 in combination with pomalidomide and low-dose dexamethasone in patients wiht relapsed-and-refractory multiple myeloma

Pilot Study of CDX-301 (rhuFlt3L) with or without Plerixa for for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs

A randomized phase III study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone (RVD) to high-dose treatment with peripheral stem cell transplant in the initial management of myeloma in patients up to 65 years og age

A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Pilot study of decitabine and haplo-identical Natural killer cells in acute myeloid leukemia

A Phase I Study of BKM120 and Rituximab in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials

Mount Sinai Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

A laboratory-based preclinical in vitro evaluation of IPH2201, a human anti-NKG2A antibody, in multiple myleoma

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with B-cell Malignancies

A phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ALN-TTRSC in patients wiht transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC)

Chronic GVHD Response Measures Validation

A pilot study of viral protein production frmo the combination of reolysin and carfilzomib in multiple myeloma

A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

OSU-14069: A randomized phase 3 study comparing conventional dose treatment using a combination of lenalidomide, bortezomib and dexamethasone (RVD) to high-dose treatment with peripheral blood stem cell transplant in the initial management of mutliple myeloma in patients up to age 65

Retrospective Review: Psychosocial Vulnerability as measured by the Transplant Evaluation Rating Scale (TERS) and Time to Hospital Readmission or Death among HSCT patients

Do graft contents predict patient outcomes following stem cell transplant in multiple myeloma?

A phase 1b trial of AR-42 with pomalidomide in relapsed multiple myeloma

A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Prospective, phase II/III, randomized clinical study to compare BEGEDINA versus " Conventional treatment"for treating steroid resistant acute graft-versus-host disease.

Chronic GVHD Response Measures Validation

A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE RECOMMENDED DOSE AND

Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

Phase 1/2 Open-Label Study Of The Safety, Tolerability And Efficacy Of The Selective Inhibitor Of Nuclear Export (Sine) Compound Kpt-8602 In Patients With Relapsed/Refractory Multiple Myeloma

Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies (MMRF-002)

A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy

A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

A Phase I open label dose escalation and randomized cohort expansion study of the safety and tolerability of elotuzumab administered in combination with either lirilumab or urelumab in subjects with multiple myeloma

Continued, Long Term follow-up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

An open-label, dose-finding study of Vedolizumab IV plus standard of care for graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patientswith High-risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Maintaining Fitness: Exercise in Patients with Hematologic Malignancy

Carfilzomib for Treatment of Chronic Graft vs. Host Disease

 

Degrees

1992 B.A., Wheeling Jesuit University

1994 M.A., Kent State University

1999 Ph.D., Kent State University

1999 M.D., Northeastern Ohio Universities College of Medicine

 

Editorial Activities

2006 - present Clinical Cancer Research
2006 - present Blood
2008 - present Bone Marrow Transplantation
2008 Cytotherapy
2011 - present Cancer Research
2012 - present First Consult
2012 - present Leukemia and Lymphoma
2012 - present International Journal of Hematologic Oncology
2013 - present Immunology Letters
2013 - present Military Medicine
2013 - present Journal of Immunology
2013 - present Drugs of the Present
2014 - present Nature Reviews Drug Discovery
2015 - present Biomed Research International
 

Honors

1988 - 1992 Loyola Scholarship.
1989 - present Gloriam Award for Leadership and Academic Excellence. Wheeling Jesuit College.
1989 - present Collegian of the Year Award. Wheeling Jesuit College.
1990 - present Gloriam Award for Leadership and Academic Excellence. Wheeling Jesuit College.
1991 - present Sportsmanship Award, Men's Soccer. Wheeling Jesuit College.
1991 - present National Honor Society for Psychology - 1990-91, chapter vice-president, 1991-92, chapter president. Psi Chi.
1991 - present National Honor Society for Philosophy. Phi Sigma Tau.
1991 - present All-Conference Scholar Athlete, Men's Soccer. Wheeling Jesuit College; West Virginia Intercollegiate Athletic Conference.
1991 - present Academic All-American Team, Men's Soccer. Wheeling Jesuit College, Wheeling, WV; National Association of Intercollegiate Athletics.
1991 - 1992 Alpha Sigma Nu, National Honor Society of Jusuit Colleges and Universities. Chapter vice-president.
1992 - present Stephen J. Laut SJ Honors Graduate. Wheeling Jesuit College.
1998 - present Alpha Omega Alpha, National Honor Society for Medicine.
1999 - present Matthew Allen Lewis Memorial Award for the Mastery of the Art and Science of Medicine. Northeastern Ohio Universities College of Medicine.
1999 - present William H Falor Award for Research. Northeastern Ohio Universities College of Medicine.
1999 - present Hoecht, Marion and Roussell Award for Outstanding Achievement. Northeastern Ohio Universities College of Medicine.
2000 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching,. University of Virginia.
2001 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching. University of Virginia.
2001 - present University of Virginia All-University Award for Excellence in Teaching. Graduate School of Arts & Sciences.
2002 - present Graduate of the Last Decade (GOLD) Award. Wheeling Jesuit University.
2002 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching. University of Virginia.
2006 - present Merit Award. American Society of Clinical Oncology.
2008 - present Team in Training "Honored Doctor" Award. The Leukemia and Lymphoma Society.
2009 - present Chairman's Citation for Outstanding Service to the Community. The Leukemia and Lymphoma Society.
2009 - present "Forty under 40" Award. Business First - Columbus OH.
2009 - present Med I/II Integrated Pathway Faculty Recognition Award. Med I/II Integrated Pathway.
2009 - present Outstanding Teaching Award. Med I/II Integrated Pathway.
2009 - present DiscoverMMORE Award. Multiple Myeloma Opportunities for Research and Education.
2010 - present Med I/II Integrated Pathway Faculty Recognition Award. Med I/II Integrated Pathway.
2011 - present Student Mentor of the Year. Department of Internal Medicine.
2011 - present Landacre Honor Society Mentor of the Year Award. Landacre Honor Society, The Ohio State University College of Medicine.
2011 - present Alpha Omega Alpha Gamma Chapter Faculty Recognition Award. Alpha Omega Alpha Medical Honor Society.
2012 Professor of the Year. The Ohio State University College of Medicine.
2013 - present Excellence in Teaching Award. Department of Internal Medicine, The Ohio State University College of Medicine.
2013 - present Courage to Teach Award. Council for Humanism, Medicine and the Arts Program, The Ohio State University College of Medicine.
2014 - present Longitudinal Practice Preceptor of the Year. College of Medicine, The Ohio State University.
2014 - present Inductee. Gold Humanism Honor Society.
2015 - present Inducted Memership. The Henry Kunkel Society, New York, NY.
2015 - present Champion of Family Medicine Award. Department of Family Medicine.
2016 - present Invited Fellowship, American College of Physicians. American College of Physicians.
2016 - 2017 Cancer Therapy Evaluation Program - National Cancer Institute - Investigator 39830. The Ohio State University Comprehensive Cancer Center.
 

Journal Articles

.

.

 

Reference Works

November 1993 Benson DM, Fountain SB, Rowan JD."Characteristics of chunking non-adjacent items in rat serial pattern learning." .
May 1994 Benson DM, Metzger MM."The effects of dl-amphetamine on environmental expectations in rats" .
May 1994 Benson DM, Fountain SB."Chunking interleaved patterns in rat serial pattern learning" .
May 1995 Benson DM, Fountain SB."Subpattern structure determines acquisition of interleaved serial patterns" .
April 1995 Benson DM."Interleaved Serial Pattern Learning" .
May 1995 Benson DM."Pattern structure influences learning and memory in rat serial pattern learning." .
May 1997 Benson DM, Fountain SB."Determining the physiological and cognitive mechanisms underlying rat serial pattern leaning" .
September 1997 Benson DM, Brautigan B, Weiner S."Diagnosing malignancy using closed bone biopsy at a small community hospital." .
May 1999 Benson DM, Fountain SB."Tracking shifted subpatterns: New evidence for rule sensitivity in rat interleaved serial pattern learning" .
May 1999 Benson DM, Fountain SB."Comparing predictive values of theories explaining rat serial performance." .
January 2000 Benson, DM Jr.."Determining the cognitive mechanisms involved in rat interleaved serial pattern learning" . : 4937-4937
September 2003 Dillingham RA, Pope JS, Benson DM, Donowitz JR."A dynamic strategy for reducing internal medicine work hours." .
January 2003 Ali, Y & Benson, DM Jr."Blood is thicker than water: a case of Waldemstrom’s macroglobulinemia and review" .
November 2004 Benson, DM, Elder P, Lin T, Blum W, Penza S, Avalos B, Byrd JC, Copelan E."Single institution experience with two high-dose chemotherapy conditioning regimens prior to autologous stem cell transplant for multiple myeloma" . : 5214
May 2005 Benson DM, Caligiuri MA."Molecular determinants of proliferative synergy between interleukin-2 and the c-kit ligand in human natural killer cells." .
November 2006 Cataland SR, Kraut EH, Benson DM, Ferketich AK, Horne A, Jin M, George JN, Wu H."Improved clinical outcomes and ADAMSTS13 activity after concurrent cyclosporine and plasma exchange in TTP" .
January 2006 Benson DM Jr, Shah MS, Freud AG, Ferketich AK, Dezube BJ, Bernstein ZP, Caligiuri MA."A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with cancer and or HIV infection." . : 2504
January 2006 Benson DM Jr, Briesewitz R, Becknell MB, Trotta R, Caligiuri MA."Synergistic proliferation in response to IL-2/15 and c-kit ligand involved both structural and functional cooperation: insights into lymphohematopoietic stem cell expansion" . : 4828
February 2007 Rice JM, Sirilla J, Krugh DW, Crawford R, Benson DM, Devine SM."Surveillance, evaluation and management of passenger lymphocyte syndrome" . : 145A
January 2008 Schwind N and Benson DM Jr.."Malignant ascites and pericardial effusion, uncommon complications of multiple myeloma" .
January 2008 Scheier B Benson DM Jr.."Effects of CD138 selection on sensitivity of FISH and cytogenetics on bone marrow aspirates from patients with multiple myeloma" .
December 2008 Hamadani,Mehdi; Blum,Kristie,A; Elder,Patrick; Lin,Thomas,S; Porcu,Pierluigi; Hofmeister,Craig,C; Blum,William; Marcucci,Guido; Benson,Don; Devine,Steven."Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas" . : 0006-4971
January 2008 Cohen J and Benson DM Jr."Effects of beta-blocker use on outcomes following high-dose chemotherapy and autologous stem cell support for multiple myeloma" .
November 2008 Blum KA, Liu Z, Lucas DM, Baiocchi R, Lin TS, Benson DM Jr , Devine SM, Jones JA, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC."Phase I evaluation of low dose decitabine targeting DNA hypermethylation in patients with CLL and NHL: dose limiting myelosuppression without evidence of hypomethylation" .
January 2008 Abuzakhm S, Benson DM Jr.."An unusual case of congestive heart failure: presenting signs and symptoms of primary systemic AL amyloidosis" .
May 2008 Awan F, Hamadani M, Lin T, Porcu P, Blum K, Benson DM Jr, Devine SM."Comparison of allogeneic versus autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma" .
November 2008 Benson DM Jr , Andritsos L, Hamadani M, Lin TS, Flynn J, Jones JA, Blum W, Elder P, Lozanski G, Byrd JC, Devine SM."NK cell immune reconstitution predicts outcomes in patients with CLL undergoing allogeneic stem cell transplantation" .
February 2008 Bechtel TP, Crawford BS, Gordon SM, Penza S, Hofmesiter C, Benson DM, Devine SM."An aprepitant containing regimen controls the delayed nausea and vomiting associated with high-dose melphalan followed by autologous peripheral blood stem cell transplantation in patients with multiple myeloma" . : 166A
December 2008 Andritsos,Leslie; Hamadani,Mehdi; Heerema,Nyla,A; Benson,Don; Hofmeister,Craig,C; Blum,William; Flynn,Joseph; Jones,Jeffrey,Alan; Elder,Patrick; Lin,Thomas,S; Lozanski,Gerard; Byrd,John,C; Devine,Steven."Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)" . : 756-757
February 2009 Hamadani M, Benson DM Jr , Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T, Marcucci G, Blum W, Devine SM."Evaluation of rabbit ATG dose intensity in patients undergoing allogeneic transplantation following reduced intensity conditioning with fludarabine, busulfan and ATG" .
February 2009 Hamadani M, Baiocchi R, Lin T, Blum KA, Ezzone S, Benson DM, Devine SM."Feasibilty of allogeneic peripheral blood stem cell transplantation (Allo-SCT) following reduced intensity conditioning (RIC) in HIV+ patients with hematological malignancies" . : 113A
January 2009 Claybon E, Smith MK, Benson DM Jr."When a flight of stairs feels like Mount Everest: dyspnea and chest pain lead to a lymphoma diagnosis. add description" .
February 2009 Grauer A, Hamadani M, Blum KA, Porcu P, Benson DM Jr , Devine SM."Allogeneic versus autologous stem cell transplantation for follicular lymphoma: The James Cancer Hospital experience" .
April 2009 Yu J, Wei M, Mao H, Hughes T, Trotta R, Park I, Hwang C, Liu S, Jarjoura D, Benson DM Jr , Caligiuri MA."CD94 defines a distinct NK1.1 mouse and CD56dim human natural killer cell subsets" .
February 2009 Benson,D,M; Hofmeister,C,C; Hamadani,M; Panzner,K; Smith,M,K; Penza,S,L; Elder,P; Krugh,D; O'Donnell,L; Devine,S,M."Pre-mobilization marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide based induction regimens" . : 1083-8791
November 2009 Pichiorri F, Suh S, de Luca L, Taccioli C, Benson DM, Hofmeister CC, Aqeilan R, Croce CM."p53 inducible microRNAs 192 and 215 regulate p53 expression and IGF1 axis in multiple myeloma" .
December 2009 Flinn,Ian,W; Byrd,John,C; Furman,Richard,R; Brown,Jennifer,R; Benson,Don,M; Coutre,Steven,E; Kahl,Brad,S; Smith,B,Douglas; Wagner-Johnston,Nina,D; Spurgeon,Stephen,E; Giese,Neill,A; Yu,Albert,S."Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110 Delta Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies" . : 380-380
January 2009 Lesinski GB, Bill MA, Fuchs JR, Li C, Bakan C, Benson DM Jr, Schwartz EB, Lin J, Hoyt DG, Fossey SL, Young GS, Warson WE III, Li PK.."Small molecule curcumin analogs induce apoptosis in human melanoma cells via STAT3 inhibition but do not alter the cellular response to immunotherapeutic cytokines." .
November 2009 Hofmeister CC, Benson DM, Efebera YA, Farag SS, Grever MR."Phase 1 trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma" .
November 2009 Benson DM Bakan CE, Alghothani L, Hofmeister CC, Efebera YA, Smith MK, Greenfield CN, Andre P, Squiban P, RomagneF, Caligiuri MA, Devine SM."Characterization of early natural killer cell reconstitution following autologous transplantation in multiple myeloma" .
November 2009 Benson,Don; Bakan,Courtney,E; Zhang,Shuhong; Alghothani,Lana; Liang,Jing; Hofmeister,Craig; Srivastava,Shivani; Smith,Megan,K; Greenfield,Carli,N; Andre,Pascale; Squiban,Patrick; Romagne,Francois; Caligiuri,Michael,A; Farag,Sherif."IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect" .
January 2009 Boore S, Smith MK, Benson DM Jr."Adult epiglottitis and multiple myeloma" .
February 2009 Hamadani M, Baiocchi R, Lin TS, Blum KA, Ezzone S, Benson DM Jr , Devine SM."Feasibility of allogeneic stem cell transplantation following RIC-conditioning in HIV positive patients with hematologic malignancies" .
April 2009 Benson DM Jr , Chandler J, Mishra A, Baiocchi R, Yu J, Lin T, Lozanski G, Devine S, Porcu P, Rotem-Yehudar R, Caligiuri MA."CT-011, a PD-1 blocking antibody, enhances NK cell function against multiple myeloma" .
December 2009 Benson DM, Romagne F, Squiban P, Wagtmann N, Farag SS, Mita A, Hofmeister CC, Smith MK, Bakan C, Caligiuri MA."Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results" .
April 2009 Pichiorri F, Sung-Suk S, Taccioli C, Hofmeister C, Benson DM, Kuehl M, Munker R, Huebner K, Aqeilan R, Croce CM."Regulation of expression of multiple microRNAs define the cellular response to non genotoxic p53 activation in multiple myeloma cells." .
June 2010 Flinn I, Byrd JC, Benson DM, Brown J, Furman RR, Coutre S, Wagner N, Spurgeon S, Smith D, Kahl B, Pratz K, Giese N, Yu A.."Interim results from a phase 1 trial of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p100d isoform, in patients with relapsed or refractory hematologic malignancies." .
September 2010 Mori S, Crawford B, Roddy J, Phillips G, Elder P, Hofmeister C, Efebera Y, Greenfield C, Rose K, Benson DM Jr."Serum free light chains add to M-protein in response assessment of newly diagnosed patients with myeloma receiving novel therapies and may hold unique, a priori prognostic power prior to HDC/SCT" .
November 2010 Kahl B, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM Jr , Furman RR, Brown JR, Coutre S, Lannutti B, Giese N, Ulrich RG, Webb HK, Peterman S, Holes L, Yu AS."Clinical safety and activity in a phase I trial of CAL-101, an isoform-selective PI3K P110 delta inhibitor, in patients with relapsed or refractory NHL" .
November 2010 Jakubowiak,Andrzej,J; Benson,Don,M; Bensinger,William; Siegel,David,S; Zimmerman,Todd,M; Mohrbacher,Ann; Richardson,Paul,G; Afar,Daniel,EH; Singhal,Anil,K; Anderson,Kenneth,C."Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study." . : 1245-1245
May 2010 Jakubowiak AJ, Benson DM, Richardson PG, Bensinger W, Siegel DSD, Zimmerman TM, Mohracker A, Afar DEH, Singhal AK, Anderson KC."Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma with 1-3 prior therapies: a phase 1 trial." .
December 2010 Habib,Joyce; Dunavin,Neil; Phillips,Gary; Elder,Patrick; Tranovich,Meaghan; Benson,Don,M; Hofmeister,Craig,C; Byrd,John,C; Devine,Steven,M; Efebera,Yvonne."Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study" . : 575-576
November 2010 Benson DM Jr, Bakan CE, Padmanaban S, Abonour R, Suvannasankha A, Jagannath S, Chari A, Clever D, Kalu C, Collins S, Alghothani Y, Hofmeister CC, Efebera Y, Blanchet S, Caligiuri MA, Farag SS."IPH2101, a novel anti-inhibitory KIR monoclonal antibody for multiple myeloma: interim phase I trial results and correlative biologic and safety data" . : 1966a
November 2010 Hofmeister,Craig,C; Bowers,Mindy,A; Lee,Seungsoo; Phelps,Mitch,A; Benson,Don,M; Kraut,Eric,H; Hicks,William,J; Deam,Deidre; Johnson,Amy,J; Farag,Sherif; Jones,Jeffrey,A; Byrd,John,C."Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia" . : 804
December 2010 Hofmeister,Craig,C; Rieser,Gisele; Bowers,Mindy,A; Merritt,Lisa,C; Greenfield,Carli,N; Efebera,Yvonne,A; Benson,Don,M; Devine,Steven,M; De Moor,Janet,S."Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors." .
June 2010 Benson DM, Padmanabahn S, Hofmeister CC, Bakan C, Abonour R, Suvannasankha A, Efebera Y, Squiban P, Caligiuri MA, Farag SS."A phase 1 trial of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma." .
December 2010 Christian,Beth; Alinari,Lapo; Earl,Christian,Tyler; Wilding,Emily; Quinion,Carl; Lustberg,Mark; Benson,Don,M; Jones,Jeffrey,A; Byrd,John,C; Wegener,William,A; Goldenberg,David,M; Baiocchi,Robert,A; Blum,Kristie,A."A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma" .
December 2010 Jones,Jeffrey,A; Andritsos,Leslie; Baiocchi,Robert; Benson,Don,M; Blum,Kristie,A; Christian,Beth; Deam,Deidre; Flynn,Joseph,M; Johnson,Amy,J; Phelps,Mitch,A; Porcu,Pierluigi; Byrd,John,C; Grever,Michael,R."Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma" . : 1169
December 2010 Dunavin,Neil; Habib,Joyce; Phillips,Gary; Elder,Patrick; Tranovich,Meaghan; Benson,Don,M; Hofmeister,Craig,C; Byrd,John,C; Devine,Steven,M; Efebera,Yvonne."Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma" .
November 2010 Furman R, Byrd JC, Brown JR, Coutre S, Benson DM Jr , Wagner-Johnston N, Flinn IW, Kahl B, Spurgeon SE, Lannutti B, Giese N, Webb HK, Ulrich RG, Peterman S, Holes L, Yu AS."CAL-101, an isoform-selective inhibitor of PI3K P110 delta, demonstrates clinical activity and PD effects in patients with relapsed/refractory CLL" .
February 2010 Hofmeister CC, Lozanski G, Baiocchi RA, Hade EM, Benson DM, Blum K, Porcu P, Byrd JC, Devine SM."Phase I study of vorinostat (SAHA) after autologous transplant for patients with high risk lymphoma" . : S204-5
February 2010 Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Stotler CJ, Remick P, Bunner S, Leadmon P, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM Jr , Devine SM."Evaluation of busulfan dose intensity in patients undergoing allogeneic transplantation with two different fludarabine/busulfan/ATG based reduced intensity conditioning regimens" .
June 2010 Jakubowiak AJ, Benson DM, Bensinger AW, Seigel DSD, Zimmerman TM, Mohracker A, Richardson PG, Afar DEH, Singhal AK, Anderson KC."Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma with 1-3 prior therapies: a phase 1 trial" .
June 2011 Collins SM, Bakan CE, Alghothani Y, Kwon H, Balasa B, Starling G, Rice A, Benson DM."The effect of elotuzumab on natural killer cell function against multiple myeloma." .
April 2011 Collins SM, Benson DM Jr."Results of a phase I trial in multiple myeloma with IPH-2101" .
May 2011 Benson DM, Bakan C, Hofmeister C, Efebera Y, Suvannasankha A, Jagannath S, Abonour R, Chari A, Padmanaban S, Romagne F, Andre P, Blanchet S, Buffet R, Caligiuri MA, Farag SS."Phase I trial of IPH-2101, a novel anti-inhibitory KIR antibody, in patients with multiple myeloma" .
February 2011 Bakan CE, Collins SM, Benson DM Jr."Lenalidomide and IPH2101, a novel anti-inhibitory KIR antibody, combine to enhance NK cell cytotoxicity against multiple myeloma" .
January 2011 Jonathon B. Cohen, Nathan Hall, Amy S. Ruppert, Jeffrey A. Jones, Pierluigi Porcu, Robert A. Baiocchi, Sam Penza, Don M Benson, Jr., Leslie A Andritsos, Joseph M. Flynn, Steven M. Devine, and Kristie A Blum."The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma" . : 3113
June 2011 Dunavin N, Wei L, Habib J, Elder P, Benson DM Jr, Hofmeister CC, Greenfield C, Rose K, Rieser G, Merritt L, Devine SM, Efebera Y."Early versus late autologous stem cell transplant in patients receiving novel therapies for multiple myeloma" . : P154
June 2011 Jakubowiak A, Benson DM, Bensinger W, Siegel D, Zimmerman T, Mohrbacher A, Richardson P, Afar D, Singhal A, Anderson KC."Dose escalation phase I trial of elotuzumab given with fixed-dose bortezomib in patients with relapsed or refractory multiple myeloma." .
February 2011 Collins S, Bakan CE, Hofmeister CC, Efebera Y, Benson DM Jr."Interim results of a phase I trial of IPH-2101, a novel anti-inhibitory KIR antibody, in patients with multiple myeloma" .
April 2011 Collins SM, Bakan CE, Benson DM Jr."Elotuzumab stimulates NK cell function against multiple myeloma" .
January 2011 Beth Christian, Lapo Alinari, Jeffrey A. Jones, Don M Benson, Jr., Joseph M. Flynn, Pierluigi Porcu, Mark E Lustberg, Mitchell Phelps, Ming Poi, Diana Chung, Carl Quinion, John C. Byrd, William Wegener, David M Goldenberg, Robert A. Baiocchi, and Kristie A. Blum."Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma," . : 3707
September 2011 Godfrey J, Benson DM."Ascending sensorimotor and autonomic dysfunction five years post-radiation therapy for Hodgkin lymphoma" .
September 2011 Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SEF, Lannutti BJ, Hsu HKW, Ulrich R, Peterman S, Holes L, Miller LL, Yu AS.."Phase I study of CAL-101, an isoform-selective inhibitory of phosphatidylinositol e-kinase P110d, in patients with previously treated chronic lymphocytic leukemia." .
November 2012 Hofmeister CC, Bowers MA, Bingman A, Lozanski G, Baiocchi RA., Falk W, Benson DM Jr, Efebera YA, Humphries K, Sell M, Greenfield CN, Lustberg ME, Vaughn JL, Tyler Earl C, Geyer S, and. Devine SM."Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma" . : 4460
November 2012 Benson DM Jr, Cohen A, Munshi NC, Jagannath S, Spitzer G, Hofmeister C, Zerbib R, Andre P, Efebera YA, Oxier S, and Caligiuri MA."A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results" . : 4058
November 2012 Hofmeister CC, Bowers MA, Efebera YA, Humphries K, Benson DM Jr, Greenfield CN, Sell M, and Devine SM."Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma" . : 3114
November 2012 Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos L A, Blum W, Klisovic RB, Penza S, Efebera YA,. Hofmeister CC, Benson DM Jr, Muthusamy N, Devine SM, and Lozanski G.."Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)" . : 4192
November 2012 McDonagh H, Falk W, Bingman A, Geyer S, Benson DM Jr, Efebera YA, and Hofmeister CC."Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma" . : 4978
November 2012 Hofmeister CC, Liu Z, Bowers MA, Porcu P, Flynn JM, Christian B, Baiocchi RA, Benson DM Jr, Andritsos LA, Greenfield CN, Sell M, Geyer S, Byrd JC, and Grever MR."Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma" . : 2955
November 2012 Stiff A, Rocci A, Hofmeister CC, Omedè P, Geyer S, Bringhen S, Cascione L, Bingman A, Gambella M, Cavallo F, De Luca L, Guan J, Larocca A, Corry J, Gay F, Efebera YA, Uccello G, Benson DM Jr, Talabere T, Murnan K, Magarotto V, Boccadoro M, Croce CM, Palumbo A, and Pichiorri F."miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients." . : 2921
November 2012 Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM Jr, Muthusamy N, Devine SM, Andritsos LA, and Lozanski G."Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease" . : 1949
November 2012 Jaglowski SM., Hofmeister CC., Elder P, Penza S, Efebera YA, Benson DM Jr, Devine S M, and Andritsos LA."The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma" . : 4286
November 2012 Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM Jr, Andritsos Leslie A, Penza Sam, Hofmeister Craig C., Geyer S, Devine SM, and Efebera YA."Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)." . : 1942
November 2013 Sborov DW, Nuovo G, Stiff A, Mace T, Lesinki G, Benson DM Jr, Efebera YA, Rosko AE, Picchiori F, Hofmeister CC."A phase I trial of reolysin alone in patients with relapsed or refractory multiple myeloma" . : 3208A
February 2013 Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, Andritsos LA, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G."Impact of atorvastatin on cellular immunome of patients undergoing allogeneic hematopoietic stem cell transplantation" . : S202A
February 2013 Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y."Lower dose of ATG decreases infection rate without increasing graft versus host disease and relapse in patients undergoing reduced-intensity allogeneic hematopoietic stem cell transplantation" . : S305A
November 2013 Benson DM, Cohen AD, Hofmeister CC, Munshi NC, Jagannath S, Efebera YA, Spitzer G, Zerbib R, Andre P, Oxier S, Caligiuri MA.". A phase I trial of anti-KIR monoclonal antibody IPH2101 and lenalidomide for multiple myeloma" . : 3181A
April 2013 Hofmeister CC, Rocci A, Geyer S, Talabere T, Omede P, Bringhen S, Cascione L, Gambella M, Stiff A, Guan J, Isaia G, Musto P, Davide R, Silvia G, Efebera Y, Uccello G, Ria R, Benevolo G, Callea V, Magarotto V, Benson DM Jr, Marcucci G, Boccadoro M, Croce CM, Palumbo A, Pichiorri F."Serum miRNAs add to ISS and FISH to predict PFS and OS in phase 3 trial" . : S221
June 2013 Leonard J, Kahl BS, Furman RR, Flinn I, Wagner-Johnston ND, Brown JR, Benson DM, Byrd JC, Spurgeon SEF, Peterman S, Johnson DM, Gu J, Dansey RD, Godfrey WR, Coutre SE."Final report of a phase 1 study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110() (PI3K) in patients with relapsed or refractory mantle cell lymphoma (MCL)" . : 297A
June 2013 Brown JR, Furman RR, Flinn IW, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SE, Benson DM, Peterman S, Li D, Dansey R, Jahn T, Byrd JC."Final results of a phase 1 study of Idelalisib (GS-1101), a selective inhibitor of PI3-Kinase-delta, in patients with relapsed or refractory CLL" .
February 2013 Akshata P, Wei L, Elder P, Falk W, Sell M, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y."Autologous hematopoietic stem cell transplant is safe and reasonable treatment in patients with primary systemic amyloidosis" . : S186A
April 2013 Chu BF, Sell M, Tucker J, Hofmeister CC, Pichiorri F, Benson DM, Efebera YA."Lenalidomide and dexamethasone therapy without autologous stem cell transplant in a patient with POEMS syndrome." . : S248
June 2013 Kahl BS, Furman RR, Flinn I, Brown JR, Wagner-Johnston ND, Coutre SE, Byrd JC, Benson DM, Spurgeon SEF, Peterman S, Johnson DM, Cho Y, Dansey RD, Godfrey WR, Leonard J."Final report of a phase 1 study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110(delta) (PI3Kdelta) in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)." . : 296A
November 2013 Pichiorri F, Rocci A, Hofmeister CC, Geyer S, Talabere T, Gambella M, Cascione L, Stiff A, Benson DM Jr, Efebera YA, Dirisala V, Smith EM, Omede P, Musto P, Rossi D, Gentili S, Uccello G, Ria R, Benevolo G, Bringhen S, Callea V, Weiss BM, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A."Circulating Mir-16 and Mir-25 as new prognosticators for multiple myeloma" . : 1853A
April 2013 Hughes T, Ciarlariello D, Bakan CE, Benson DM Jr."The role of aryl hydrocarbon receptor activation in multiple myeloma" . : S61-2
June 2013 Spurgeon SE, Wagner-Johnston ND, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Leonard J, Peterman S, Johnson D, Gu J, Godfrey WR, Kahl BS."Final results of a phase 1 study of idelalisib, a selective inhibitor of PI3K-delta in patients with relapsed or refractory mantle cell lymphoma (MCL)." . : 8519A
June 2013 Benson DM, Kahl BS, Furman RR, Brown JR, Wagner-Johnston ND, Coutre SE, Spurgeon SE, Byrd JC, Leonard J, Peterman S, Johnson D, Cho Y, Godfrey WR, Flinn IW."Final results of a phase 1 study of idelalisib, a selective inhibitor of PI3K delta in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)" . : 8526A
April 2013 Hofmeister CC, Benson DM."Low testosterone is associated with shorter PFS in multiple myeloma" . : S211
February 2013 Cohen JB, McBride A, Geyer S, Bingman A, Elder P, Blum W, Klisovic R, Penza S, Andritsos LA, Benson DM, Efebera Y, Hofmeister CC, Garzon R, Marcucci G, Devine SM."Improved survival of patients with acute graft-versus-host disease during recent years: impact of donor and recipient characteristics" . : S320A
June 2013 Flinn I, Brown JR, Byrd JC, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SEF, Benson DM, Peterman S, Johnson DM, Li D, Dansey RD, Joahn TM, Furman RR."Final report of a phase 1 study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110(delta) (PI3Kdelta) in patients with relapsed or refractory CLL" . : 295A
June 2013 Brown JR, Furman RR, Flinn IW, Coutre SE, Wagner-Johnston ND, Kahl BS, Spurgeon SE, Benson DM, Peterman S, Johnson D, Li D, Jahn T, Byrd JC."Final results of a phase 1 study of idelalisib (GS-1101) a selective inhibitor of PI3K in patients with relapsed or refractory CLL" . : 7003A
November 2013 Coutre SE, Leonard JP, Barrientos JC, De Vos S, Flinn I, Furman RR, Brown JR, Wagner-Johnston N, Benson DM Jr, Schreeder MT, Sharman JP, Boyd T, Spurgeon S, Zelenetz AD, Lamanna N, Kipps TJ, Kahl BS, Bello CM, Burger JA, Rai KR, Dansey R, Kim Y, Holes LM, Lazarov M, Dubowy RL, O’Brien SM."Clinical activity of idelalisib (GS-1101), a selective inhibitor of PI3Kd, in phase I and II trials in chronic lymphocytic leukemia (CLL): Effect of Del(17p)/TP53 mutation, Del(11q), IGHV mutation and NOTCH1 mutation" . : 1632A
November 2013 Chu J, Deng Y, Benson DM Jr, He S, Hughes TL, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J."CS1-specific chimeric antigen receptor (CAR)-engineered NK cells and T cells enhance in vitro and in vivo anti-tumor activity against human multiple myeloma" . : 14A
November 2014 Rosko AE, Hofmeister CC, Benson DM, Efebera YA, Huang Y, Burd C."T-cell p16ink4a expression increases post-transplant in patients with multiple myeloma" . : 2020A
November 2014 Martin TG, Baz R, Benson DM, Lendvai N, Campana F, Charpentier E, Vij R."A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma" . : 83A
November 2014 Vasu S, Geyer S, Bingman A, Jaglowski S, Elder P, O’Donnell L, Bradbury H, Kitzler R, Andritsos LA, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister CC, Benson DM, Muthusamy N, Lozanski G, Devine SM."Allograft T-cell, T-regs, and NK cell and B cell content influence distinct clinical outcomes following g-CSF mobilized hematopoietic stem cell transplantation" . : 3929A
November 2014 Efebera YA, Geyer S, Bingman A, Kitlzer R, Elder P, Andritsos LA, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Coombes K, Lozanski G.". Impact of atorvastatin on cellular immunome of patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT)" . : 1166A
November 2014 Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennelly C, Cortright K, Andritsos LA, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Lozanski G, Devine SM."Phase II trial evaluating the safety and efficacy of atorvastatin for the prophylaxis of acute graft versus host disease (aGVHD) in patients with hematologic malignancies undergoing HLA-matched related donor allogeneic hematopoietic stem cell transplantation (allo HSCT)." . : 3929A
November 2014 Sborov D, Lamprecht M, Benson DM, Tackett K, Efebera YA, Roscko AE, Devine SM, Poi M, Phelps MA, Hofmeister CC."2 hour cryotherapy effectively reduces severe mucositis associated with high-dose melphalan followed by autologous stem cell rescue: results from a randomized trial" . : 3960A
November 2014 Cordero H, Sborov DW, Canella A, Liu Z, Consiglio J, Ni W, Smith E, Rizzotto L, Efebera YA, Benson DM, Cascione L, Mo X, Byrd JC, Grever MR, Hofmeister CC, Pichiorri F."HDAC inhibitor AR-42 decreases CD44 expression and sensitives myeloma cells to lenalidomide" . : 3377A
June 2014 Martin T, Hsu K, Charpentier E, Vij R, Baz RC, Benson DM, Lendvai N."A phase Ib dose escalation trial of SAR650984 (anti-CD38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma" . : 8512A
October 2015 Marsh L, Benson DM."First report of progressive multi-focal leukoencephalopathy Central nervous system infection with JC virus in a patient treated with pomalidomide" .
November 2015 Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic RB, Vasu S, Blum B, Jaglowski S, Devine SM, Efebera YA."Comparison of two doses of antithymocyte globulin (ATG) in reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplant (alloSCT)." . : 4328A
November 2015 Efebera YA, Rosko AE, Hofmeister CC, Benner J, Bakan CE, Stamper K, Lamb T, Devine H, Sell M, Avigan DE, Benson DM."First interim results of a phase I/II study of lenalidomide in combination with anti-PD-1 monoclonal antibody MDV9300 (CT-011) in patients with relapsed / refractory multiple myeloma" . : 1838A
November 2015 Ciarlariello D, Harshman S, Canella A, Hade E, Rocci A, Palumbo A, Hofmeister CC, Freitas M, Benson DM, Pichiorri F."Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers" . : 1814A
November 2015 Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine SM, Wiles TM, Gillahan J, Jones D, Huang Y, Burd CE."Geriatric assessment metrics are associated with hospital length of stay in pre-bone marrow transplant myeloma patients" . : 3200A
October 2015 Cooperrider J, Benson DM."Expression of NKG2A on NK cells in the setting of immune reconstitution post-stem cell translate inversely correlates with remission time in myeloma" .
November 2015 Sborov DW, Pichiorri F, Nuiovo GJ, Benson DM, Efebera YA, Rosko AE, Hofmeister CC."Reolysin combined with carfilzomib for treatment of relapsed multiple myeloma patients" . : 1835A
Vij R, Martin T, Lendvain I, Campana F, Baz R, Benson DM."Phase 1b trial of isatuximab (SAR650984) in combination with lenalidomide / dexamethasone for relapsed / refractory multiple myeloma" .
Rosko A, Jaglowski Sm Hofmeister CC, Benson DM, Efebera YA, Burd K."Examining the relationship between T cell p16INK4a levels and immunosenescence and geriatric assessments in patients with multiple myeloma" .

Inventions and Patents

Buckeye Surveillance, Contact and Research for Multiple Myeloma

METHODS AND COMPOSITIONS FOR TREATING MULTIPLE MYELOMA BY TARGETING THE ARYL HYDROCARBON RECEPTOR

 

Presentations

The Challenges of Jesuit Education

Reflects on Jesuit Education

User's Guide: M1 Curriculum at NEOUCOM

User's Guide: M2 Curriculum at NEOUCOM

User's Guide: M3 Curriculum at NEOUCOM

State of the Art: Treatment of intracranial metastatic malignancy.

Humility and Courage

CRH-induced metabolic disarray associated with prostate cancer paraneoplastic syndrome

Molecular determinants of proliferative synergy between interleukin-2 and the c-kit ligand in human natural killer cells

A dynamic strategy for reducing internal medicine work hours

Spirituality and Religion at the End of Life

Re-slicing the American Health Care Pie, when we really need loaves and fishes: American health care delivery integrated with Catholic medical ethics.

Blood is thicker than water: a case of Waldemstrom’s macroglobulinemia and review

Molecular mechanisms of cytokine directed natural killer cell based therapyproliferation: from basic science to clinical applications

Non-hodgkin lymphoma for the family practitioner.

Natural Killer cells and amyloidosis: mechanism and translation

Natural Killer cells and amyloidosis: therapeutic potential and promise.

“Why should patients with cancer participate in clinical trials?�

NK cell therapy for cancer

Hematology Board Review

Multiple Myeloma, new updates

Multiply Myeloma: translating discoveries into emerging therapies

10 things you need to know about Multiple Myeloma

Hematology emergencies

Amyloidosis update

Multiple Myeloma: translating new evidence into clinical practice.

Hematology Board Review

Restoring and augmenting natural killer cell immunity in patients with B-Cell malignancies

Promising research in multiple myeloma

The role of natural killer cells in hematopoietic stem cell and solid organ transplantation

Promising research in multiple myeloma

Natural Killer Cell Immunity in Chronic Lymphocytic Leukemia

Multiple Myeloma review

The promise of natural killer cells in cancer therapy: from bench to bedside.

2009 ASH Review

Emerging front line therapies for multiple myeloma

What is Amyloidosis?

Seminar series: Diagnosis and Management of Multiple Myeloma

Hematology Board Review

Augmenting natural killer cell function: towards a novel therapeutic strategy in patients with multiple myeloma

Hope from a physician-scientist's perspective: advances in the research and treatment of multiple myeloma

"Hope" from a physician-scientist’s perspective: advances in the research and treatment of multiple myeloma

Augmenting natural killer cell function for myeloma therapy

Update in Blood Cancer Research

On suffering: a Catholic perspective

Natural killer cell cytotoxicity is enhanced via therapeutic targeting of the PD-1/PD-L1 signaling axis.

Update on induction regimens for multiple myeloma

Towards a Phase II trial of CT-011, an anti-PD-1 antibody, and lenalidomide for patients with multiple myeloma: translation of preclinical evidence and study design

Cases in abnormal hematology

Pelotonia funding for cancer research at The James

Invited Chair and Moderator: Session 103: Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and other infections: NK cells, Immunotherapy and Infections

What is an immunoglobulin?

Cancer Research at The James

The promise of current research in blood cancers

The future of treatment for multiple myeloma

Updates in Hematology from the 2011 ASCO meeting

“End-of-life issues from a Catholic perspective”

ASH review and update on multiple myeloma

The past, present and future of multiple myeloma

Research advances in blood cancer

Updates in blood cancer research

Immune function in myeloma patients and elotuzumab function in NK cells

Febrile Neutropenia

Multiple myeloma: update on current management

Cancer, an overview

Be smart, work hard, and care

Cancer treatment: how to make informed decisions about standard of care and clinical trials

The role of hematopoietic stem cell transplantation in multiple myeloma

Creating a pathway to promotion for clinicians: a panel discussion

Myeloma update: ASCO 2013

Myeloma and the kidney

Making the most of your summer research experience

Career opportunities in Internal Medicine

Research Updates

A case of atypical HUS/TTP in a 52 year old woman

Update on amyloidosis for the general internist

Update in multiple myeloma

Natural killer cell manipulation for myeloma therapy

Multiple myeloma subspecialty board review

Amyloidosis: update on pathogenesis and therapy

Multiple myeloma and chronic lymphocytic leukemia

KIR-ative intent

Career opportunities in Internal Medicine

Augmenting NK cell cytotoxicty against cancer

2014 ASH Review: Updates on Myeloma

Dual antibody therapies for multiple myeloma

Career Exploration Panel

 

Professional Activities

present Pelotonia presentation at The Ohio State University Greek Leadership Meeting. The Ohio State University.
present Pelotonia: How is the money invested?. Pelotonia on behalf of Bath and Body Works "high rollers".
present Pelotonia 2013: How the money is invested. Team Granville Peloton.
present Cancer Research Lecture. Pelotonia for Limited Brands.
present Pelotonia presentation and laboratory tour. Pelotonia for Anomatic Corporation Peloton.
present How we will cure cancer with your help. Team in Training Inspiration Dinner - Leukemia and Lymphoma Society.
present Limited Brands Pelotonia kickoff event. Limited Brands.
present Ride with us: GREEK involvement in Pelotonia. The Ohio State University Greek Society.
present Pelotonia Rider Recruitment Event Emcee. Pelotonia.
present Pelotonia: where does the money go?. Pelotonia for Huntington Bank "high rollers".
present Continental Office Supply Corporation Pelotonia kickoff event. Continental Office Supply Corporation.
present Huntington Bank Pelotonia kickoff event. Huntington Bank.
2007 - present Team in Training / Columbus Marathon. Leukemia and Lymphoma Society. Columbus, OH.
2007 - present Leukemia and Lymphoma Society. Team in Training. Columbus, OH.
2007 - present MMORE. Multiple Myeloma Opportunities for Research and Education. Columbus, OH.
2008 - present Amyloidosis Support Network. Amyloidosis Support Network.
2008 - present Leukemia and Lymphoma Society. Leukemia and Lymphoma Society.
2008 - present Consultant. Innate Pharma, Inc..
2008 - present Consultant. new Mentor.
2008 - present Consultant. CureTech, LTD.
2009 - present Consultant. Facet Biotechnology.
2009 - present Consultant. Abbott Laboratories.
2009 - present Consultant. North American Center for Continuing Medical Education.
2009 - present Consultant. Bristol Myers - Squibb.
2009 - present Rider, Speaker, & Volunteer. Pelotonia. Columbus, OH.
2009 - present Pelotonia. Pelotonia. Columbus, OH.
2010 - present Scientific Advisory Board. Multiple Myeloma Opportunities for Research and Educaiton (MMORE). Columbus, OH.
2011 - present Columbus Marathon. Team in Training. Columbus, OH.
2012 - present Pelotonia rider recruitment speaker. Pelotonia. Columbus, OH.
2006 - 2009 Consultant. Novo Nordisk, Inc..
2007 - 2010 Wheeling Jesuit University - Member of Board of Directors. Wheeling Jesuit University.
2011 Host and Presenter. Pelotonia Laboratory Tours. Columbus, OH.
 

Technical Reports

“Special Report on ASCO 2006: Anemia, Neutropenia, and Mucositis. A continuing education newsletter for physicians, nurses and pharmacists.”

 

Unpublished Works

Interfeon mediates immunoevasion of innate immunity in multiple myeloma

Extracellular vesicle expression of inhibitory ligands promotes NK cell immune evasion in myeloma

AHR as a pontential therapeutic target in multiple myeloma

Checkpoint inhibition in myeloma.

Anti-CD38 monoclonal antibody isatuximab (SAR650984) with lenalidomide and dexamethasone, for relapsed/refractory multiple myeloma: an open-label phase Ib study

Current and future immunotherapeutic approaches to multiple myeloma therapy